As of 2025-07-16, the EV/EBITDA ratio of SkinBioTherapeutics PLC (SBTX.L) is -20.00. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SBTX.L's latest enterprise value is 41.53 mil GBP. SBTX.L's TTM EBITDA according to its financial statements is -2.08 mil GBP. Dividing these 2 quantities gives us the above SBTX.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.3x - 8.9x | 7.6x |
| Forward P/E multiples | 6.7x - 8.4x | 7.6x |
| Fair Price | (5.35) - (6.74) | (6.04) |
| Upside | -132.9% - -141.5% | -137.2% |
| Date | EV/EBITDA |
| 2025-07-14 | -20.00 |
| 2025-07-11 | -20.46 |
| 2025-07-10 | -20.62 |
| 2025-07-09 | -20.62 |
| 2025-07-08 | -20.62 |
| 2025-07-07 | -20.62 |
| 2025-07-04 | -20.46 |
| 2025-07-03 | -20.31 |
| 2025-07-02 | -20.31 |
| 2025-07-01 | -20.31 |
| 2025-06-30 | -20.68 |
| 2025-06-27 | -20.68 |
| 2025-06-26 | -20.46 |
| 2025-06-25 | -20.00 |
| 2025-06-24 | -19.69 |
| 2025-06-23 | -20.31 |
| 2025-06-20 | -20.46 |
| 2025-06-19 | -20.46 |
| 2025-06-18 | -20.77 |
| 2025-06-17 | -20.46 |
| 2025-06-16 | -20.00 |
| 2025-06-13 | -21.24 |
| 2025-06-12 | -21.70 |
| 2025-06-11 | -21.39 |
| 2025-06-10 | -22.32 |
| 2025-06-09 | -22.63 |
| 2025-06-05 | -23.09 |
| 2025-06-04 | -22.94 |
| 2025-06-03 | -23.40 |
| 2025-06-02 | -23.25 |
| 2025-05-30 | -23.09 |
| 2025-05-29 | -23.25 |
| 2025-05-28 | -23.09 |
| 2025-05-27 | -23.71 |
| 2025-05-23 | -23.09 |
| 2025-05-22 | -23.25 |
| 2025-05-21 | -23.25 |
| 2025-05-20 | -23.09 |
| 2025-05-19 | -23.09 |
| 2025-05-16 | -24.02 |
| 2025-05-15 | -23.71 |
| 2025-05-14 | -24.33 |
| 2025-05-13 | -24.64 |
| 2025-05-12 | -24.64 |
| 2025-05-09 | -24.89 |
| 2025-05-08 | -24.39 |
| 2025-05-07 | -26.49 |
| 2025-05-06 | -27.11 |
| 2025-05-02 | -28.04 |
| 2025-05-01 | -28.66 |